Article
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.
Nature communications - 20 Oct 2022
Herbst Sophie A, Vesterlund Mattias, Helmboldt Alexander J, Jafari Rozbeh, Siavelis Ioannis, Stahl Matthias, Schitter Eva C, Liebers Nora, Brinkmann Berit J, Czernilofsky Felix, Roider Tobias, Bruch Peter-Martin, Iskar Murat, Kittai Adam, Huang Ying, Lu Junyan, Richter Sarah, Mermelekas Georgios, Umer Husen Muhammad, Knoll Mareike, Kolb Carolin, Lenze Angela, Cao Xiaofang, Österholm Cecilia, Wahnschaffe Linus, Herling Carmen, Scheinost Sebastian, Ganzinger Matthias, Mansouri Larry, Kriegsmann Katharina, Kriegsmann Mark, Anders Simon, Zapatka Marc, Del Poeta Giovanni, Zucchetto Antonella, Bomben Riccardo, Gattei Valter, Dreger Peter, Woyach Jennifer, Herling Marco, Müller-Tidow Carsten, Rosenquist Richard, Stilgenbauer Stephan, Zenz Thorsten, Huber Wolfgang, Tausch Eugen, Lehtiö Janne, Dietrich Sascha
Abstract excerpt
Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains to be established in clinically heterogeneous cancer entities such as chronic lymphocytic leukemia (CLL). Here, we characterize the proteome and transcriptome alongside...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.